Ransom Advisory Ltd Acquires Shares of 240 The Clorox Company $CLX

Ransom Advisory Ltd bought a new position in The Clorox Company (NYSE:CLX) during the 1st quarter, HoldingsChannel reports. The fund bought 240 shares of the company’s stock, valued at approximately $35,000.

A number of other hedge funds have also made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Clorox by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company’s stock valued at $170,406,000 after buying an additional 41,485 shares in the last quarter. Woodline Partners LP boosted its position in Clorox by 253.7% in the first quarter. Woodline Partners LP now owns 10,407 shares of the company’s stock valued at $1,532,000 after buying an additional 7,465 shares in the last quarter. Empowered Funds LLC raised its stake in shares of Clorox by 109.9% in the first quarter. Empowered Funds LLC now owns 46,534 shares of the company’s stock valued at $6,852,000 after acquiring an additional 24,360 shares during the last quarter. MBB Public Markets I LLC acquired a new position in shares of Clorox in the 1st quarter worth approximately $322,000. Finally, Meiji Yasuda Asset Management Co Ltd. grew its position in Clorox by 1,215.5% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 52,134 shares of the company’s stock worth $7,677,000 after acquiring an additional 48,171 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Stock Performance

CLX stock opened at $124.44 on Friday. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The company has a 50 day moving average price of $124.30 and a 200 day moving average price of $132.67. The Clorox Company has a fifty-two week low of $116.53 and a fifty-two week high of $171.37. The stock has a market capitalization of $15.22 billion, a PE ratio of 19.09, a price-to-earnings-growth ratio of 0.99 and a beta of 0.52.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the company posted $1.82 EPS. Clorox’s revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Clorox Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Wednesday, August 13th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $4.96 dividend on an annualized basis and a yield of 4.0%. This is a boost from Clorox’s previous quarterly dividend of $1.22. Clorox’s dividend payout ratio (DPR) is presently 76.07%.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares of the company’s stock, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Wells Fargo & Company cut their price objective on Clorox from $138.00 to $130.00 and set an “equal weight” rating for the company in a research report on Friday, September 5th. Citigroup reaffirmed a “neutral” rating and issued a $135.00 price target (down from $140.00) on shares of Clorox in a report on Tuesday, July 15th. JPMorgan Chase & Co. increased their price objective on shares of Clorox from $133.00 to $135.00 and gave the stock a “neutral” rating in a report on Monday. Barclays lowered their price objective on shares of Clorox from $129.00 to $119.00 and set an “underweight” rating for the company in a research report on Tuesday, July 15th. Finally, UBS Group reduced their target price on shares of Clorox from $150.00 to $134.00 and set a “neutral” rating on the stock in a research report on Thursday, July 17th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Clorox presently has an average rating of “Reduce” and a consensus target price of $142.18.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.